DEEPAK FERTILIZERS (DEEPAKFERT) - MULTIBAGGER ANALYTICAL EVALUATION

Analysis Date: August 6, 2026
Price (as-of): ₹1,553.90 | Market Cap: ₹19,646 Cr | TTM P/E: 26.6x

1. Catalyst Evaluation & Ramp-Aware Impact Math

• The Filing: On August 6, 2026, DEEPAKFERT filed investor conference call updates detailing its historic Q1 FY27 performance along with project updates.
• Freshness Check: The core Q1 FY27 financial performance (PAT doubling to ₹490 Cr, 22% revenue growth to ₹3,256 Cr) and project completion metrics were initially disclosed in filing on July 30, 2026. Hence, already_priced_in is marked TRUE as the market has absorbed the main earnings surprise (stock already up 52.7% over 6 months).
• Capacity Expansion Math:
• Major Capex: Dahej Acid project (₹1,983 Cr) and Gopalpur TAN facility are 93% and 96% complete respectively.
• Ramp Schedule: Commercial production expected in H2 FY27 with full capacity utilization expected by FY28-FY29.
• Revenue & EPS Impact:
  • TTM Base Revenue (FY26): ₹11,506 Cr.
  • Year-1 Revenue Uplift (FY27): ~14% (driven by partial commissioning and strong pricing, bringing FY27 revenue to ~₹13,100 Cr).
  • Steady-State Revenue Uplift (FY28/29): ~25% over FY26 base (~₹14,400–15,000 Cr annual run-rate).
  • Earnings Power: Q1 FY27 produced ₹490 Cr PAT (~₹38.8 EPS for the single quarter). Standardizing EBITDA margins around 20-22% once backward-integrated gas-to-ammonia flows optimize, normalized annual PAT is expected at ₹1,350–1,500 Cr, yielding a steady-state EPS of ~₹108–118 per share (+85% uplift over FY26 EPS of ₹58.40).

2. Quality Gate & Fundamental Profile

• Quality Gate: FAILED (Informational). Trailing ROCE stands at 8.0%, depressed due to the massive capital investment cycle prior to project commissioning. However, management targets >20% project ROCE once fully operational.
• Balance Sheet & Leverage: Net debt / EBITDA has improved significantly from 2.86x down to 1.4x. Total Debt stands at ₹826 Cr against Net Worth of ₹3,661 Cr (D/E: 0.23).
• Promoter Alignment: Stable at 45.63% over recent quarters without pledge concerns.

3. Industry Context & Moat

• Capital Intensity: HIGH. Chemical and fertilizer synthesis requires multi-thousand-crore asset creation.
• Execution Complexity: Medium. Regulatory, safety, and supply-chain integration factors mean a 12 to 24-month operational ramp after mechanical completion.
• Industry Growth CAGR: ~11% structurally in industrial acids, specialty fertilizers (Croptek), and technical ammonium nitrate (mining expansion).

4. Valuation & Scenario Calibration

• Base Case (35-45% upside over 24 months): Commissioning of Dahej and Gopalpur completes smoothly in H2 FY27. EBITDA margins stabilize near 21%. FY28 EPS reaches ~₹110. Applying a normalized P/E of 20x yields a target price of ~₹2,200 (+41.5%).
• Bull Case (80% upside): Full capacity utilization achieved ahead of schedule; global ammonia spread remains favorable; B2C TAN share grows to >25%. EPS expands to ₹135 with P/E re-rating to 21x, targeting ~₹2,835 (+82.4%).
• Bear Case (-22% downside): Geopolitical friction/tariffs inflate imported feedstock costs; delay in plant stabilization compresses margins back to 14%. EPS drops to ₹65. At 18x P/E, stock retraces to ~₹1,170 (-24.7%).

5. Final Verdict & Rationale

• Verdict: POSSIBLE | Multibagger Score: 68/100
• Rationale: Deepak Fertilizers shows a classic structural inflection—massive ongoing capex turning operational in H2 FY27, backed by strong deleveraging and high current quarter earnings momentum. However, because trailing ROCE is currently modest (8.0%), earnings have historical cyclicality tied to global ammonia prices, and the stock has already run up 52.7% over 6 months with the immediate earnings news known since July 30, it qualifies as a POSSIBLE multibagger rather than a top-tier strong candidate until post-commissioning ROCE expansion is fully demonstrated.

Deep Dive Analysis: Deepak Fertilisers & Petrochemicals Corp. Ltd. (DEEPAKFERT)

Analysis Date: 2026-07-30
Current Price: ₹1,626.3 | Market Cap: ₹20,562 Cr

1. Catalyst & Ramp-Aware Impact Math

• Announcement Summary: In Q1 FY27, DEEPAKFERT achieved a 101% YoY increase in consolidated PAT to ₹490 Cr on a 22% YoY increase in revenue to ₹3,256 Cr. EBITDA margin surged to 26.0%. Management confirmed the impending Q2 FY27 commissioning of two major mega-projects:
  1. Dahej Nitric Acid Project: ₹1,983 Cr capex establishing DEEPAKFERT as Asia's largest producer.
  2. Gopalpur TAN Project: ₹2,675 Cr capex adding 376 KTPA (+64% capacity increase), bringing total AN capacity to ~1.0 MMTPA.
• Combined Capex: ₹4,658 Cr (~40.5% of TTM revenue ₹11,506 Cr).
• Execution & Ramp Timeline: Mechanical completion scheduled for Q2 FY27 with commercial production ramping up over 2.5 years (FY27 to FY29).
• Revenue Uplift Calculations:
• Year 1 Uplift: Assuming ~35-40% utilization of new capacities in H2 FY27, revenue increment is estimated at ₹1,400-1,500 Cr (~12.5% over FY26 TTM revenue of ₹11,506 Cr).
• Steady-State Uplift (FY29): At 85-90% utilization and an estimated asset turnover of 0.8x-0.9x, additional steady-state annual revenue will be ~₹3,700 Cr (+32% steady-state uplift).
• Margin & Earnings Flow-Through:
• Assuming normalised EBITDA margins of 20-22% on expanded revenues (specialty shift + backward integration benefits) vs historical 14.6%-18.7%, annual steady-state incremental EBITDA will be ~₹800 Cr.
• Accounting for incremental depreciation and finance costs, steady-state incremental net profit is projected at ₹400-450 Cr.
• Expected steady-state EPS uplift: +55% over FY26 EPS of ₹58.40, reaching ~₹90-92/share by FY28/FY29.

2. Industry Dynamics & Quality Assessment

• Capital Intensity: HIGH. Chemical & fertiliser projects require massive upfront capex and 2-3 years for full operational stabilisation.
• Industry CAGR: Structural demand for Technical Ammonium Nitrate (mining/infrastructure) and specialty crop nutrition is projected at 9-11% CAGR over the next 5-7 years.
• Quality Gate Check: Trailing ROCE of 8.0% is depressed due to heavy Capital Work in Progress (CWIP) of over ₹4,500 Cr yet to generate revenue. With target project ROCEs >20%, post-commissioning capital efficiency will improve substantially.

3. Financial & Operational Growth Profile

• Quarterly Acceleration: Revenue moved from ₹2,658.75 Cr (Q1 FY26) to ₹3,256.0 Cr (Q1 FY27), while PAT doubled from ₹243.86 Cr to ₹490 Cr, showcasing operational leverage.
• De-leveraging Momentum: Net Debt/EBITDA improved rapidly to 1.40x in June 2026 from 2.86x in March 2026 due to internal cash flow generation.
• Promoter Holding: Stable at 45.63% with zero pledge concerns reported.

4. Valuation Context & Scenario Analysis

• Trailing P/E: 27.8x (vs Peer Median 44.8x).
• Base Case (18-36 Months): Successful commissioning in Q2 FY27 and steady ramp-up to 80% capacity by FY28. EPS reaches ~₹90. Target P/E of 27x gives a target price of ~₹2,470 (+52% upside).
• Bull Case: Faster capacity absorption, sustained 25%+ EBITDA margins on favorable global TAN/ammonia spreads. EPS reaches ~₹105. Target P/E of 30x gives a target price of ~₹3,150 (+95% upside).
• Bear Case: Raw material cost spikes (Ammonia import disruptions) and delay in capacity utilization. EPS normalises near ₹65. Valuation compresses to 19x P/E, giving a target price of ~₹1,220 (-25% downside).

5. Verdict Rationale

DEEPAKFERT presents a high-conviction growth inflection point as ~₹4,660 Cr worth of major projects transition from non-earning CWIP into operational cash-generating assets starting Q2 FY27. Strong Q1 FY27 numbers (+101% PAT YoY) validate operational leverage. Trailing ROCE is artificially low due to CWIP and will expand sharply as these assets ramp up.